Clinical Trial: Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07651475) titled 'Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)' on June 11.

Brief Summary: The purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: R/R AML

Intervention: DRUG: BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF

BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, chidamide, and G-CSF

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: Liping Dou

Information provided by (Responsible Party): Liping Dou, Chinese PLA General Ho...